Full history for every metric is available with a Kvantra account
BiondVax Pharmaceuticals Ltd. (BVXV)
Key financial summary
Financials in ILS| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | ILS m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | ILS m | -11 | -9 | |||||
| Net profit | ILS m | -35 | -23 | -124 | 7 | -51 | -1 | - |
| EPS reported | ILS | -0.20 | - | |||||
| Operating cashflow per share | ILS | -2.80 | -2.80 | |||||
| Capex per share | ILS | 0.32 | 0.32 | |||||
| FCF per share | ILS | -3.13 | -3.13 | |||||
| Free cash flow | ILS m | -8 | 9 | |||||
| Net debt | ILS m | 7 | 16 | |||||
| Book value equity | ILS m | -2 | -7 | |||||
| Book value per share | ILS | -0.68 | -2.10 | |||||
| Number of shares | m | 2.59 | 3.38 | |||||
| DPS (TTM paid) | ILS | 0.00 | 0.00 |
Financial summary
Financials in ILS| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -15.28 | -2.13 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -3.32 | 1.68 | |||||
| EV/EBITDA LTM | x | -3.27 | 29.76 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -1.97% | -4.93% | |||||
| FCF Yield | % | -30.12% | 59.63% | |||||
| Quality | ||||||||
| ROE | % | 30.17% | -4.92% | |||||
| ROIC | % | -4.04% | -4.04% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | -100.00% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.38 | 0.37 | |||||
| Net Debt/EBITDA | x | -0.71 | -0.71 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | 27.76% | 104.05% | |||||
| Net debt/Equity | x | -4.24 | -2.22 | |||||
| Gross debt/equity | x | -12.24 | -3.46 | |||||
Company overview
BiondVax Pharmaceuticals Ltd. is an Israeli-based biopharmaceutical company currently in its development stage. Its core mission involves the research, production, and market introduction of therapeutic products designed for the prevention and treatment of a range of infectious and other medical conditions. The company has established strategic licensing and collaboration agreements with prominent scientific institutions, notably the Max Planck Society and the University Medical Center Göttingen. These partnerships are geared towards the advancement and commercialization of nanosized antibodies (NanoAbs), including a specific candidate for COVID-19, and extending this technology to address various other disease indications. Founded in 2003, BiondVax maintains its corporate headquarters in Jerusalem, Israel.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
BiondVax Pharmaceuticals Ltd. (BVXV)
BiondVax Pharmaceuticals Ltd. is an Israeli-based biopharmaceutical company currently in its development stage. Its core mission involves the research, production, and market introduction of therapeutic products designed for the prevention and treatment of a range of infectious and other medical conditions. The company has established strategic licensing and collaboration agreements with prominent scientific institutions, notably the Max Planck Society and the University Medical Center Göttingen. These partnerships are geared towards the advancement and commercialization of nanosized antibodies (NanoAbs), including a specific candidate for COVID-19, and extending this technology to address various other disease indications. Founded in 2003, BiondVax maintains its corporate headquarters in Jerusalem, Israel.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free